Big Pharma-backed Sitryx Locks an Additional $39M in a Series A Raise to Advance its Immunometabolic Pipeline September 28, 2023
Sitryx Raises Additional $39 Million to Progress Development of Disease-modifying Therapeutics for Chronic AutoImmune and Inflammatory Disease September 27, 2023
Sitryx Therapeutics Strengthens Leadership Team With Appointment of Ravi M. Rao as Chief Medical Officer April 12, 2022
Sitryx Licenses Intellectual Property Rights for Inhibitors of a New Target in Immunometabolism from Cancer Research UK in Exclusive Worldwide Agreement July 12, 2021
